UNITY Biotechnology finds that their senolytic UBX1325 matched aflibercept's efficacy in a 36-week Phase 2b trial for diabetic macular edema, promoting similar vision gains by targeting senescent retinal cells and offering a potential new therapy path.
Key points
Completed 36-week Phase 2b ASPIRE clinical trial for UBX1325 in patients with advanced diabetic macular edema.
UBX1325 achieved statistically non-inferior Best-Corrected Visual Acuity improvements compared to aflibercept at week 36.
Mechanism centers on clearance of senescent retinal cells to reduce inflammation and improve vision.
Subgroup comprising 60% of participants exhibited relative UBX1325 superiority in moderately aggressive DME phenotype.
UNITY Bio explores partnerships, mergers, or asset sales to advance its senolytic pipeline and UBX1325.
Why it matters:
These findings validate senolytic therapy as a viable strategy for treating diabetic macular edema by focusing on cellular senescence, a paradigm shift from purely anti-VEGF approaches. UBX1325’s comparable efficacy and targeted mechanism could streamline future ophthalmic drug development and enhance patient outcomes.
Q&A
What is a senolytic?
How does UBX1325 differ from anti-VEGF therapies?
What is Best-Corrected Visual Acuity (BCVA)?
Why did the trial miss its primary endpoint at weeks 20–24?
Read full article
Academy
Cellular Senescence and Senolytic Therapies: A Primer
Cellular senescence refers to a state in which cells irreversibly stop dividing in response to stress or damage. While senescence helps prevent cancer by halting growth of damaged cells, accumulation of these non-dividing cells can drive tissue dysfunction through chronic inflammation and secretion of harmful factors, known as the senescence-associated secretory phenotype (SASP). Eliminating senescent cells has emerged as a promising strategy to restore tissue homeostasis and treat age-related diseases.
Senolytic therapies are drugs designed to selectively induce death of senescent cells without harming healthy cells. Researchers identify proteins and pathways on which senescent cells depend for survival—such as members of the BCL-2 family or the p16Ink4a pathway—and develop agents to inhibit these targets. Effective senolytics clear senescent cells, reduce inflammation, and improve tissue function in preclinical models of fibrosis, osteoarthritis, and cardiovascular disease.
Mechanisms of action for senolytics vary by compound class. Small molecules may block anti-apoptotic signals within senescent cells, while antibody–drug conjugates can deliver toxins directly to cell-surface markers unique to senescent cells. Delivery routes include systemic administration for widespread conditions or localized injections—such as intravitreal injections for eye diseases—to maximize on-target effects and minimize systemic exposure.
Applications in ocular diseases like diabetic macular edema (DME) are driven by chronic inflammation and vascular dysfunction in the retina. Standard treatments use anti-VEGF agents to reduce fluid leakage from retinal blood vessels. Senolytic therapies add a complementary approach by clearing senescent cells that perpetuate inflammation and tissue breakdown. Early clinical data for UBX1325 demonstrate vision improvements comparable to anti-VEGF therapy, highlighting senolytics’ potential in ophthalmology.
Advantages over existing methods include potential for longer-lasting efficacy, reduced injection frequency, and treatment of underlying aging mechanisms rather than solely symptomatic relief. Combining senolytics with anti-VEGF drugs may further enhance outcomes and slow disease progression by addressing multiple pathological pathways.
Challenges and future directions involve optimizing dosing regimens, ensuring precise targeting of senescent cells, and monitoring long-term safety and tolerability. Researchers are also developing biomarkers to identify senescent cell burden, improving patient selection, and exploring combinatorial approaches with regenerative therapies to maximize benefits in ocular and systemic age-related conditions.
Key takeaways
- Senescent cells drive chronic inflammation across tissues.
- Senolytic drugs selectively clear aged cells to restore function.
- UBX1325 shows promise in treating diabetic macular edema.
- Clinical trials continue to refine safety and efficacy profiles.